Another phase I study, PILOT, included IMAB362 plus zoledronic acid (ZA) and a low-to-medium dose interleukin 2 (IL-2) in patients with advanced GC and esophagogastric junction adenocarcinoma. Here, IL2 is linked to gastroesophageal junction adenocarcinoma.